Frankfurt am Main, May 29, 2015 -- Moody's Investors Service has today affirmed GlaxoSmithKline plc's (GSK) A2 long-term issuer rating and (P) P-1 short-term rating and changed the outlook of GSK to negative from stable reflecting the rating agency's view that over the next 2 or 3 years GSK may find it difficult to restore credit metrics in line with our expectations for the current rating.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.